This study successfully established a new protocol for the differentiation of visceral sensory ganglion organoids (VSGOs) from human induced pluripotent stem cells (iPSCs).

This study further proved that chemical reprogramming technology can induce Chemically induced dedifferentiation of human cells and successfully prepare large-scale expanded embryonic limb budd-like precursor cells.

In recent years, stem cell therapy has become a research hotspot in the biomedical field, and donor stem cells have been used for decades in multiple research and clinical treatments.

On October 7, 2024,"Analysis of the National Burden and Risk Factors of Diabetes in China from 1990 to 2021: Results of the Global Disease Burden Study in 2021" was released in the Journal of Diabetes.

This paper reports for the first time in the world a clinical study of using islet cell transplantation prepared from chemically reprogrammed induced pluripotent stem cells to treat type 1 diabetes.

This study constructed human pluripotent stem cell (hPSC)-derived vascularized macrophage-islet organoids (VMI organisms).

Mesenchymal stem cells are expected to provide a new treatment path for patients with type 2 diabetes.

TED-A9 is an investigational cell therapy designed to replace lost ventral midbrain specific dopaminergic cells in patients with Parkinson's disease.